Health
Ivonescimab Shows Promise as Perioperative Treatment for Resectable Lung Cancer
A phase 2 clinical trial published in Nature Medicine indicates that perioperative ivonescimab significantly reduces viable tumor cells in patients with resectable non-small cell lung cancer. While the results suggest a robust biological signal, researchers caution that randomized phase 3 trials are required to confirm clinical utility.